Frederic Sweeney's Biography

Frederic Sweeney, Senior Director, T2 Biosystems

Dr. Frédéric Sweeney joined T2 Biosystems in February 2013 to lead the business development activities of the company. His career spans academic research, venture capital and private equity, as well as operations. Prior to joining T2 Biosystems, Fred was Vice-President of Business Development & Strategic Alliances for Tornado Spectral Systems (TSS), a commercial stage nanophotonics and spectroscopy technology company strongly driven by an OEM partnership business model. Having joined as an original founding member of the company, Fred managed all aspects of commercialization and go-to-market strategy for TSS’ product portfolio. He led a number of large partnership agreements with world-leading spectroscopy companies and several in/out-licensing deals. Fred also worked as part of the life sciences investment team at VenGrowth Private Equity Partners, one of Canada’s premier private equity and venture capital firms. His main responsibilities at VenGrowth were to provide operational support and coordinate follow-on investments for portfolio companies, as well as sourcing and performing due diligence on new investment opportunities for the firm. Fred also acted as an observer on the Board of numerous companies in the medical device, therapeutic, diagnostic and biomaterials space. Fred holds a Ph.D. in molecular and medical genetics from the University of Toronto as a Terry Fox Scholar of the National Cancer Institute of Canada. During his scientific training, he acquired a deep expertise in clinical diagnostics and cancer biology by using structural and molecular biology as well as small molecule biochemistry.